Semaglutide Linked to Lower Psychiatric Hospitalization Risk in Bipolar Disorder Study

A large-scale study analyzing data from nearly 15,000 Swedish individuals with bipolar disorder has revealed a potential link between the use of semaglutide, the active ingredient in Ozempic and Wegovy, and a reduced risk of psychiatric hospitalization. The research, published in Acta Psychiatrica Scandinavica and spanning prescriptions from 2009 to 2024, compared patients to themselves during periods with and without GLP-1 receptor agonist medication.

Researchers found that during periods when patients took semaglutide, their risk of psychiatric hospitalization decreased by 21%. This effect was specific to semaglutide; other tested drugs from the same class, liraglutide and dulaglutide, did not show a significant association with reduced hospitalizations, suggesting the effect may not be solely due to weight loss.

Professor Mark Taylor of Griffith University, who led the study, stated that individuals with bipolar disorder who took semaglutide exhibited significantly lower rates of psychiatric hospitalization compared to periods when they were not on GLP-1 medications. He noted that the findings add to growing evidence that GLP-1 receptor agonists might offer benefits beyond treating diabetes and obesity.

The proposed biological explanation suggests that GLP-1 signaling may protect the brain by reducing inflammation and cellular stress, both of which have been linked to bipolar disorder. The presence of GLP-1 receptors in the brain, not just the digestive system, supports the theoretical possibility of such a cerebral effect.

While the study's self-controlled design helps mitigate confounding factors like disease severity or socioeconomic status, the researchers emphasize that it is observational and cannot establish causality. They recommend further investigation through controlled trials. Limitations include potential biases in treatment initiation and the fact that the study sample was exclusively Swedish, with healthcare systems and prescription patterns that may not be universally applicable.

This research emerges in the context of previous investigations into the psychiatric effects of weight-loss drugs. Earlier concerns about suicidal ideation were largely dismissed by European drug regulators, with some studies even indicating a lower risk of such thoughts among users. Taylor commented that, contrary to initial reports, these medications appear safe from a psychiatric perspective, and this new study shifts the focus from potential safety concerns to potential therapeutic benefits.